Lesigercept
Phase 2Protein / enzyme
Lesigercept is one of 10 small molecule programs targeting Chronic Spontaneous Urticaria. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
9
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
12 competitors in Chronic Spontaneous Urticaria
#DrugCompanyPhaseTrials
1Claritin
PPerrigo Company
Approved
ICP-332
BBeijing InnoCare Pharma Tech Co., Ltd.
Phase 3
Barzolvolimab
CCelldex Therapeutics
Phase 3
JYB1904
JJemincare
Phase 3
LOU064
NovartisPhase 3
CM512
KKeymed Biosciences Co.Ltd
Phase 2
Human Interleukin-2 (IL-2) (proleukin)
NNova Scotia Health Authority
Phase 3
Lesigercept
YYuhan Corporation
Phase 2
BGB-16673
BBeOne Medicines
Phase 1
BBT001
BBambusa Therapeutics
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Lesigercept. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Protein / enzyme[2]
- Highest Phase
- Phase 2[1]
- Company
- YYuhan Corporation